Edition:
United Kingdom

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.70USD
23 Feb 2018
Change (% chg)

$-0.01 (-1.41%)
Prev Close
$0.71
Open
$0.71
Day's High
$0.72
Day's Low
$0.70
Volume
5,200
Avg. Vol
92,562
52-wk High
$2.47
52-wk Low
$0.45

Select another date:

Thu, Feb 15 2018

BRIEF-Concordia International Says UK Competition, Markets Authority Notified Co It Is Closing Investigation Related To Fusidic Acid Eye Drops

* CONCORDIA INTERNATIONAL CORP - UK COMPETITION AND MARKETS AUTHORITY NOTIFIED CO THAT IT IS CLOSING ITS INVESTIGATION RELATED TO FUSIDIC ACID EYE DROPS

BRIEF-Concordia International To Defer Payment Of About $37.5 Mln Interest Due Dec 15

* CONCORDIA INTERNATIONAL CORP - ‍DETERMINED TO DEFER PAYMENT OF APPROXIMATELY $37.5 MILLION OF INTEREST DUE DEC 15 ON 9.5% SENIOR UNSECURED NOTES​

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

UPDATE 1-Drug firm Concordia overcharged Britain's health service with 6,000 pct price rise

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

Britain says Canada's Concordia overcharging health service for thyroid drug

LONDON, Nov 21 Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.

BRIEF-Concordia International ‍comments on UK CMA statement of objections related to Liothyronine

* ‍COMMENTS ON CMA STATEMENT OF OBJECTIONS RELATED TO LIOTHYRONINE; SAYS "DO NOT BELIEVE THAT COMPETITION LAW HAS BEEN INFRINGED​"

BRIEF-Concordia International Q3 ‍reported revenue $154.6 mln

* Concordia International announces third quarter 2017 results

BRIEF-Concordia International seeks to realign capital structure under CBCA

* Concordia International Corp. takes next step to realign its capital structure by commencing proceedings under the Canada Business Corporations Act

BRIEF-Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million

* Concordia International - ‍decided to use a 30-day grace period to defer payment of about $26 million of interest due oct 16 on its $735 million unsecured notes​

Select another date: